S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

from OncLive® On Air · host OncLive® On Air

Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.

Episode metadata supplied by the publisher feed · Published Jul 15, 2024

Embed this episode

Attribution link and audio player

Ready to play

S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

0:00 10:35

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 10 minutes long.

This episode was published on July 15, 2024.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!